Skip to main content

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

jjcush@gmail.com
Nov 17, 2026 1:40 pm

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for people living with PMR. 

PMR affects an estimated 966,000 Americans, roughly 0.7% of adults aged 50 and older. This disorder of elderly adults is disabling, and is commonly treated with steroids, but relapses are frequent, affecting up to 40% of patients in the first year. This is the second drug approval (sarilumab and secukinumab) that can be viewed as steroid-sparing therapy.  Secukinumab is already approved for use by the EMA in Europe and in the USA, PMR is now 11th indication for use in inflammatory disorders. 

FDA approval is based on the results of the pivotal phase III REPLENISH trial, wherein secukinumab (SEC) doubled the likelihood of sustained remission while permitting an effective steroid taper. In the REPLENISH trial, SEC 150 mg doubled the rate of sustained remission compared with (40.5% vs. 20.5%) at week 52. Data also showed SEC had significant steroid-sparing effects and reduced cumulative steroid exposure vs. placebo.

While being a steroid sparing option for PMR, there remains a significant over-reliance and overuse of corticosteroids in elderly (usually caucasian) PMR patients. The challenge is in identifying the optimal patient ASAP to avoid steroid related toxcities, such as osteoporosis, fractures, cardiovascular disease and diabetes, and to ultimately avoid PMR relapses.

Package insert particulars:

  • Indication: adults who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper
  • Doseage: Recommended dosage is 150 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter, in combination with a tapering course of glucocorticoids. In PMR, SEC can be used alone following discontinuation of glucocorticoids
  • Warnings
    • Infection: Serious infections have occurred. Exercise caution when considering the use of SEC in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue SEC until the infection resolves.
    • Tuberculosis: Evaluate for TB prior to initiating treatment
    • Inflammatory Bowel Disease (IBD): Cases of IBD were observed in clinical trials
    • Eczematous Eruptions: Cases of severe eczematous eruptions have occurred in patients receiving SEC
  • Geriatrics: 52 PMR subjects exposed to subcutaneous SEC in the REPLENISH clinical trial, 196 (78%) were 65 years of age or older, and 74 (29%) were 75 years of age or older. No overall differences in safety or efficacy of SEC have been observed between subjects 65 years of age and older and younger adult subjects

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures

Disclosures
The author has no conflicts of interest to disclose related to this subject
×